Literature DB >> 26029496

Genome Editing of the Blood: Opportunities and Challenges.

Matthew H Porteus1.   

Abstract

The ability to remove blood cells, including hematopoietic stem cells (HSCs), from a person and then re-transplant them (hematopoietic stem cell transplantation (HSCT) is a well-established treatment paradigm that can be used in both the autologous setting or in the allogeneic setting. Using allogeneic HSCT can cure different genetic diseases of the blood but has significant limitations. An alternative to allogeneic HSCT is to transplant genetically modified HSCs instead. A powerful approach to the precision modification of HSCs is to use genome editing whereby the genome is modified with spatial precision (at an exact location) in the genome and sometimes with nucleotide precision (the exact nucleotide changes are introduced). The progress and challenges of genome editing of blood are discussed.

Entities:  

Keywords:  CRISPR/Cas9; Genome editing; TAL effector nuclease; engineered nuclease; homologous recombination; non-homologous end-joining; zinc finger nuclease

Year:  2015        PMID: 26029496      PMCID: PMC4444059          DOI: 10.1007/s40778-014-0003-z

Source DB:  PubMed          Journal:  Curr Stem Cell Rep


  37 in total

1.  Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor.

Authors:  P Bousso; V Wahn; I Douagi; G Horneff; C Pannetier; F Le Deist; F Zepp; T Niehues; P Kourilsky; A Fischer; G de Saint Basile
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease.

Authors:  Jizhong Zou; Prashant Mali; Xiaosong Huang; Sarah N Dowey; Linzhao Cheng
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

3.  An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level.

Authors:  Daniel E Bauer; Sophia C Kamran; Samuel Lessard; Jian Xu; Yuko Fujiwara; Carrie Lin; Zhen Shao; Matthew C Canver; Elenoe C Smith; Luca Pinello; Peter J Sabo; Jeff Vierstra; Richard A Voit; Guo-Cheng Yuan; Matthew H Porteus; John A Stamatoyannopoulos; Guillaume Lettre; Stuart H Orkin
Journal:  Science       Date:  2013-10-11       Impact factor: 47.728

4.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases.

Authors:  Fyodor D Urnov; Jeffrey C Miller; Ya-Li Lee; Christian M Beausejour; Jeremy M Rock; Sheldon Augustus; Andrew C Jamieson; Matthew H Porteus; Philip D Gregory; Michael C Holmes
Journal:  Nature       Date:  2005-04-03       Impact factor: 49.962

5.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Authors:  Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez
Journal:  Nat Med       Date:  2006-04-02       Impact factor: 53.440

6.  Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin.

Authors:  Jacob Hanna; Marius Wernig; Styliani Markoulaki; Chiao-Wang Sun; Alexander Meissner; John P Cassady; Caroline Beard; Tobias Brambrink; Li-Chen Wu; Tim M Townes; Rudolf Jaenisch
Journal:  Science       Date:  2007-12-06       Impact factor: 47.728

7.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

8.  Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo.

Authors:  Nathalia Holt; Jianbin Wang; Kenneth Kim; Geoffrey Friedman; Xingchao Wang; Vanessa Taupin; Gay M Crooks; Donald B Kohn; Philip D Gregory; Michael C Holmes; Paula M Cannon
Journal:  Nat Biotechnol       Date:  2010-07-02       Impact factor: 54.908

9.  A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity.

Authors:  Claudio Mussolino; Robert Morbitzer; Fabienne Lütge; Nadine Dannemann; Thomas Lahaye; Toni Cathomen
Journal:  Nucleic Acids Res       Date:  2011-08-03       Impact factor: 16.971

10.  Promoterless gene targeting without nucleases ameliorates haemophilia B in mice.

Authors:  A Barzel; N K Paulk; Y Shi; Y Huang; K Chu; F Zhang; P N Valdmanis; L P Spector; M H Porteus; K M Gaensler; M A Kay
Journal:  Nature       Date:  2014-10-29       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.